# What This Bill Does

Congress is trying to block a new rule from the Food and Drug Administration (FDA) about laboratory-developed tests. These are medical tests that labs create and use in-house rather than buying from commercial manufacturers. The FDA had announced this new rule on May 6, 2024, and this bill is essentially Congress saying "we don't want this rule to go into effect."

# Why This Matters

Laboratory-developed tests are used for all kinds of medical diagnoses—everything from cancer screening to genetic testing to COVID-19 detection. Right now, these tests operate in a gray area with minimal FDA oversight. The FDA's new rule would have brought these tests under stricter regulation, meaning labs would need to prove their tests are accurate and reliable before using them on patients. This bill would prevent that from happening, keeping the current system where labs have more freedom to develop and use these tests with less government scrutiny.

# Who Gets Affected

If this bill passes, patients could continue getting medical tests that haven't been formally validated by the FDA, which means there's less guarantee those tests are actually accurate. On the flip side, laboratories and hospitals would avoid the costs and paperwork of meeting new FDA requirements. Some people see this as protecting innovation and keeping healthcare costs down, while others worry it means patients might rely on unreliable test results without knowing it. The practical impact depends on whether you value less regulation and lower costs, or more government oversight to ensure medical tests are trustworthy.

Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".